Definium Therapeutics Inc. Common Shares (DFTX)
NASDAQ: DFTX · Medicinal Chemicals & Botanical Products · New York, NY
Our rating: Cautious
Cautious reaffirmed at $34.64, low conviction, November 10, 2026.
Breaks if: The cautious call is wrong if Definium reports a confirmed pivotal-trial success or regulatory approval within the next 12 months and the stock holds above $46.00 — roughly 33% above today's $34.64 — for at least 20 consecutive trading days following that disclosure. That combination would demonstrate pipeline value the available figures cannot support today.
Key figures
| Market value | $3.9B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$337M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −61.4% |
| Beta to the S&P 500 | 1.56 |
| Volatility, annualized | 75.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-0.46 | n/a |
| June 30, 2026 | n/a | n/a | $-1.44 | n/a |
| March 31, 2026 | n/a | n/a | $-0.71 | n/a |
| December 31, 2025 | n/a | n/a | $-0.50 | n/a |
| September 30, 2025 | n/a | n/a | $-0.78 | n/a |
| June 30, 2025 | n/a | n/a | $-0.50 | n/a |
| March 31, 2025 | n/a | n/a | $-0.35 | n/a |
| December 31, 2024 | n/a | n/a | $-0.42 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 3%, Gemini 5%, Mistral 5%
23 ledger entries and 21 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.